Cancer Care's AIDS Pain Booklet Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS: Control Your Pain So It Doesn't Control You," that provides information about pain management to people with HIV, to help them advocate for themselves and receive

NEW YORK--Cancer Care, Inc. has a new booklet, "Pain in HIV/AIDS:Control Your Pain So It Doesn't Control You," that provides informationabout pain management to people with HIV, to help them advocate for themselvesand receive effective pain management. For free copies, call Cancer Careat 212-221-3300 or toll-free at 1-800-813-4673.

Articles in this issue
New Board to Deal With Cancer Policy Issues
MoAb Shows Positive Results in Lymphoma Patients
Prostate Cancer Gene Location Narrowed to Chromosome 1 Arm
New BCG Bladder Cancer Indication Gets Panel Nod
Panel Advises FDA To OK Letrozole for Advanced Breast Cancer
Limited Diagnostic Testing After Breast Cancer Treatment Urged
Pressures of Managed Care Spur Interest in Clinical Guidelines
Baltimore Will Head New Effort To Develop a Vaccine for HIV
Epidemiologist Challenges Tamoxifen, Second Cancer Link
Cancer Care's AIDS Pain Booklet Available
AIDS Center Director Offers Advice on Selecting a Physician
Good Outcomes Seen With Hyperfractionated Conformal RT
Goals of Planned National Pain Research Consortium Outlined
New Evidence Supports Screening in Younger Women
Interferon Improves Survival in CML
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Related Content
Current data support prospective studies comparing IDH-triplet vs IDH-doublet therapies among patients with IDH-mutant acute myeloid leukemia.

IDH-Triplet Therapy Shows Excellent Outcomes in IDH-Mutant AML

Russ Conroy
July 7th 2025
Article

Current data support prospective studies comparing IDH-triplet vs IDH-doublet therapies among patients with IDH-mutant acute myeloid leukemia.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.

Patient Enrollment for Phase 3 UGN-103 Trial in LG-IM-NMIBC Complete

Tim Cortese
July 7th 2025
Article

The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

FDA OKs NGS Test for Tumor Profiling, as CDx for Sunvozertinib in NSCLC

Roman Fabbricatore
July 7th 2025
Article

The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors

Roman Fabbricatore
July 7th 2025
Article

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.